可靠性强化试验技术在某型伺服作动器研制中的适用性探索

目的探索可靠性强化试验技术在典型机电液一体化产品伺服作动器研制过程中的适用性。方法以某型伺服作动器为研究对象,从故障激发的角度对可靠性强化试验技术的应用进行可行性分析,在响应调查和应力分析的基础上,结合产品的工作特点设计适用于该类伺服作动器的可靠性强化试验方案,包含低温步进应力试验、高温步进应力试验、快速温度循环试验10个循环、振动步进应力试验(包含气锤式三轴向六自由度超高斯随机振动方式及电磁振动台随机振动方式)及综合环境应力试验5个循环,并依此进行试验。结果在快速温度循环试验及综合环境应力试验过程中,均有效地激发出了产品的漏油故障,与相似产品外场暴露的漏油故障模式相吻合。结论可靠性强化试验技术可有效地应用于典型机电液一体化产品伺服作动器的研制过程,设计的可靠性强化试验方案可有效地激发外场出现频率较高的故障,可作为该类产品研制的试验手段之一。     

空间站控制力矩陀螺微振动测试技术

目的分析控制力矩陀螺的微振动扰动特性。方法通过获取陀螺连接点对结构的扰振力输出、关键部位的微振动响应来获取产品的微振动扰动特性,通过隔振的方式对外部环境的干扰进行隔离,进而降低测试的背景噪声,通过运用高精度测试传感器来实现微小扰动力信号、加速度信号的测量,利用结构有限元法及单点激励多点响应的模态分析方法校核系统刚度,进而确定测试频率范围是否满足需求。结果可同时获得空间站控制力矩陀螺连接点处的输出扰振力、质心处的输出扰振力合力、合力矩以及关键部位的微振动响应,可有效隔离外部干扰,扰振力背景噪声的时域信号最大值可控制在0.07 N以内,RMS值在0.02 N以内,加速度信号的时域背景噪声最大值可控制在1.5 mg以内,RMS值在0.1 mg以内。可识别微小扰振信号,加速度传感器分辨率为5×10-5 grms,力传感器的测量分辨率为1×10-2 N,力矩测量分辨率小于1×10-2 N·m。测试频带在320 Hz以内。结论满足型号需求,并投入型号使用。     

机械强化污泥回流式一体化活性污泥法的运行机理研究

活性污泥通过机械搅拌强化污泥内循环回流,提高了污泥的活性,并且使污泥浓度可达到4.5kg/m3,用该机械强化污泥回流式一体化活性污泥法处理小区生活污水,当水力停留时间为3h,溶解氧为2.2mg/L,机械搅拌速度为250r/min时,CODcr、氨氮去除率均可达到83% 以上,出水达到国家污水排放一级标准.该一体化活性污泥法简单易行,运行成本低,投资小,操作维护方便,是生活小区生活污水适宜的处理工艺技术.     

Prenatal diagnosis of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency by steroid analysis in the amniotic fluid of mid-pregnancy: Comparison with HLA typing in 17 pregnancies at risk for CAH

Amniotic fluid (AF) levels of 17-hydroxyprogesterone (17OHP) and testosterone (T) were determined at 16–17 weeks in 17 pregnancies at risk for CAH and results compared to 75 normal controls. The fetus was predicted to be unaffected in 12 cases on the findings of normal AF levels of both 17OHP and T and the latter allowed a correct prediction of fetal sex in all instances. HLA typing confirmed normality in 12 cases revealing 5 carriers, 5 homozygous normal and 2 indeterminate. Steroid levels of the 2 groups were similar. Three fetuses were predicted to be CAH affected on unambiguously high levels of 17OHP and T (in female only). HLA typing was in agreement, and the diagnosis was confirmed in 2 abortuses and a female newborn by physical and hormonal studies. In the last 2 cases AF levels of OHP and T were normal but HLA (A/B/C) genotypes were identical to the CAH affected siblings. Normal physical and hormonal findings in the 2 aborted fetuses would exclude the possibility of an in utero virilizing form of CAH. The discrepancy could be explained on the basis that the fetuses had an allelic form of 21-hydroxylase deficiency or on the basis of recombination (not fully tested). It is concluded that a fully informative prenatal diagnosis of CAH should not rely entirely on HLA typing but on hormonal studies.     

污水处理厂污泥脱水滤液循环利用的研究

对污水处理厂污泥机械脱水滤液进行了循环利用研究。将滤液与剩余污泥（mlsss≤13000mg／l）按1比4的比例均匀混合。然后加入到沉淀器中进行重力浓缩试验，结果表明：它能够改善污泥的浓缩脱水性能，加快污泥的沉淀速度，增大浓缩污泥的浓度；生产运行数据分析显示：污泥脱水滤液与剩余污泥混合液进入浓缩池后，上清液更加清澈，污泥的固体负荷率显著提高，这既可降低污泥的处理成本，亦可减少污泥处理系统的基建投资，为污泥处理系统的工艺优化开辟了新途径。     

Prenatal diagnosis of spinal muscular atrophy in Russia

Ninety-two families with spinal muscular atrophy (SMA) applied for genetic counselling and further prenatal diagnosis. To minimize expenses, only one tightly linked informative marker was determined in the course of preliminary examination, and non-radioactive allele detection was preferably used. Four prenatal diagnoses of SMA type I, four of SMA type II, and one of SMA type III were made. This trial programme shows the considerable requirements, importance, and potential effectiveness of prenatal prediction of SMA in Russia.     

海水环境下玻璃纤维增强复合材料力学性能演化规律研究

目的 研究海水环境下海流能发电机组叶片用玻璃纤维复合材料力学性能的变化规律.方法 在实验室内通过海水浸泡试验、拉伸试验、弯曲试验以及剪切试验,测定叶片用玻璃纤维树脂基复合材料的吸水特性,以及在人工海水介质中各项力学性能参数的演变规律.结果 随着浸泡时间的增加,玻璃纤维树脂基复合材料吸水率先逐步增大、后趋于稳定,总吸水率约0.075％.抗拉强度呈先降低、后提高、又降低的趋势,抗拉强度最高可超过1100 MPa,最小值约为940 MPa.弹性模量和弯曲强度呈逐渐降低的趋势,弹性模量降幅约9.5％,弯曲强度降幅约为30％.弯曲模量变化起伏不定,变化幅度在15％以内.材料剪切强度呈先增大、后降低的趋势,最小值为189 MPa,较初始值高10 MPa.剪切模量呈先降低、后提高的现象,在浸泡28 d时,剪切模量最小,为16.4 GPa.结论 玻璃纤维增强树脂基复合材料经过长期海水浸泡后,拉伸及抗剪切性能略有降低,但降幅不大,抗弯性能下降明显,需要在叶片结构设计和强度计算时,充分考虑抗弯性能衰减的负面影响.     

Neural tube defects in trisomy 18

In a retrospective survey, the incidence of neural tube defects in liveborn trimsomy 18 was found to be 6·2 per cent. Based on these data one would expect to find trisomy 18 in 1 of the 117 patients with myeloidysplasia; the incidence of trisomy 18 in dysraphic fetuses would be anticipated to be higher. These observations underscore the need for amniocentesis karyotyping of fetuses with neural tube defects, and the importance of careful examination of infants born with neural tube defects.     

Technical and theoretical considerations in the HLA typing of amniotic fluid cells for prenatal diagnosis and paternity testing

HLA typing of amniotic fluid cells has been used for the prenatal diagnosis of the HLA linked diseases congenital adrenal hyperplasia (21-OH-deficiency (21-OH-def) type) and complement C4 deficiency and it has also been used for the prenatal de termination of paternity. There are, however, technical difficulties in this test associated with the weak expression of some B locus antigens on amniotic fluid cells, and theoretical difficulties related to associations between particular HLA antigens and the 21-OH-def allele. Since certain HLA-B locus antigens are found in significantly increased frequencies among patients with 21-OH-def, there is a relatively high incidence of HLA-B homozygosity among the patients and over 40 percent of the parents of these patients share one or more HLA-B locus antigens. Results of some prenatal HLA typing tests may thus be difficult to interpret, and supplementary tests should be used whenever possible. HLA typing of amniotic cells is, however, the only available procedure for prenatal diagnosis of C4 deficiency and it is the best available procedure for prenatal determination of paternity. A modification of our original procedure allows HLA typing to be performed with increased numbers of HLA typing sera, and sera with optimum reactivity for amniotic fluid cells have now been selected for the definition of most of the more commonly expressed HLA antigens. Although amniotic fluid cells do not express DR antigens, amniotic fluid cells can be typed for the HLA-linked marker glyoxalase I (GLO) and this may be the informative for prenatal diagnosis in some cases.